Reuters logo
3 个月前
BRIEF-Protalix Biotherapeutics announces positive results from phase II clinical trial of Alidornase Alfa
2017年4月12日 / 下午12点46分 / 3 个月前

BRIEF-Protalix Biotherapeutics announces positive results from phase II clinical trial of Alidornase Alfa

1 分钟阅读

April 12 (Reuters) - Protalix Biotherapeutics Inc

* Protalix Biotherapeutics announces positive results from phase II clinical trial of Alidornase Alfa (air dnase) for the treatment of cystic fibrosis

* Protalix Biotherapeutics Inc - sixteen patients were enrolled in study, all of whom completed study

* Protalix Biotherapeutics Inc - Alidornase Alfa was well tolerated with no serious adverse events reported

* Protalix Biotherapeutics - adverse events that occurred during study were mild and transient in nature for phase ii clinical trial of Alidornase Alfa

* Protalix Biotherapeutics - in vitro study of air dnase showed significant inhibition of pseudomonas aeruginosa Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below